2004 Annual Meeting | Neurology of Sleep

Date Sunday 04/25/04

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Beth A. Malow, MD, MS, FAAN

Topic(s) Sleep

Learning Objectives Upon completion:
Participants should become familiar with major advances in specific sleep disorders including narcolepsy, obstructive sleep apnea, circadian rhythm disorders, and parasomnias.

The American Board of Psychiatry and Neurology has reviewed Neurology of Sleep and has approved this product as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Academician, Resident

Event Timeline
09:00 AM - 09:50 AM		Obstructive Sleep Apnea: Neural Control of the Pharyngeal Musculature David P. White, MD
09:55 AM - 10:45 AM		New Therapeutic Advances in Narcolepsy Emmanuel Mignot, MD, PhD
10:45 AM - 11:00 AM		Break
11:00 AM - 11:50 AM		Paroxysmal Events in Sleep and Daytime Sleep Attacks Beth A. Malow, MD, MS, FAAN
11:55 AM - 12:45 PM		Circadian Rhythms: Implications for Sleep and Neurological Disorders Phyllis C. Zee, MD, PhD

Faculty Disclosures
Beth A. Malow, MD, MS, FAAN	Dr. Malow has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurim Pharmaceuticals. The institution of Dr. Malow has received research support from National Institutes of Health. The institution of Dr. Malow has received research support from Department of Defense. The institution of Dr. Malow has received research support from PCORI.
Emmanuel Mignot, MD, PhD	Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals, Inc. . Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for EcoR1. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for ApneaCo. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa .
David P. White, MD	No disclosure on file
Phyllis C. Zee, MD, PhD	Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Apnimed. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CVS Caremark. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony. Dr. Zee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony Biosciences. Dr. Zee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals Inc.. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apnimed. Dr. Zee has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for World Sleep Society. An immediate family member of Dr. Zee has stock in Teva. The institution of Dr. Zee has received research support from National Institutes of Health. The institution of Dr. Zee has received research support from Sleep Number. Dr. Zee has received intellectual property interests from a discovery or technology relating to health care. Dr. Zee has received intellectual property interests from a discovery or technology relating to health care. Dr. Zee has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��